Clinical and Laboratory Findings for 12 Patients With CML
| Patient No. . | Age/Sex . | Mos . | Therapy . | WBC . | Hb . | Plt . | Karyotype . |
|---|---|---|---|---|---|---|---|
| 1 | 71/F | 36 | IFN + HU | 5,400 | 8.3 | 66.1 | 46,XX,t(9;22)(q34;q11)[20] |
| 2 | 72/F | 80 | HU | 4,800 | 10.9 | 22.4 | 46,XX,der(9)inv(9)(p11q13)t(9;22)(q34;q11),der(22)t(9;22)(q34;q11)[20] |
| 3 | 47/M | 87 | HU | 5,000 | 11.4 | 27.5 | 46,XY,t(9;22)(q34;q11)[20] |
| 4 | 52/F | 39 | HU | 5,800 | 11.6 | 54.0 | 46,XX,t(9;22)(q34;q11)[20] |
| 5 | 82/M | 22 | HU | 8,000 | 11.1 | 27.0 | 46,XY,t(9;22)(q34;q11)[20] |
| 6 | 37/M | 86 | IFN + HU | 3,200 | 14.3 | 23.7 | 46,XY,t(9;22)(q34;q11)[20] |
| 7 | 68/F | 117 | HU | 4,600 | 9.5 | 10.7 | 46,XX,t(9;22)(q34;q11)[20] |
| 8 | 19/M | 0 | None | 138,800 | 12.4 | 54.2 | 46,XY,t(9;22)(q34;q11)[20] |
| 9 | 69/F | 65 | HU | 6,100 | 7.5 | 72.5 | 46,XX,t(8;9;22)(p23;q34;q11)[20] |
| 10 | 40/F | 0 | None | 37,800 | 8.6 | 30.9 | 46,XX,t(9;22)(q34;q11)[20] |
| 11 | 31/M | 0 | None | 67,500 | 14.6 | 32.0 | 46,XY,t(9;22)(q34;q11)[20] |
| 12 | 39/M | 0 | None | 104,800 | 13.3 | 17.1 | 46,XY,t(9;22)(q34;q11)[20] |
| Patient No. . | Age/Sex . | Mos . | Therapy . | WBC . | Hb . | Plt . | Karyotype . |
|---|---|---|---|---|---|---|---|
| 1 | 71/F | 36 | IFN + HU | 5,400 | 8.3 | 66.1 | 46,XX,t(9;22)(q34;q11)[20] |
| 2 | 72/F | 80 | HU | 4,800 | 10.9 | 22.4 | 46,XX,der(9)inv(9)(p11q13)t(9;22)(q34;q11),der(22)t(9;22)(q34;q11)[20] |
| 3 | 47/M | 87 | HU | 5,000 | 11.4 | 27.5 | 46,XY,t(9;22)(q34;q11)[20] |
| 4 | 52/F | 39 | HU | 5,800 | 11.6 | 54.0 | 46,XX,t(9;22)(q34;q11)[20] |
| 5 | 82/M | 22 | HU | 8,000 | 11.1 | 27.0 | 46,XY,t(9;22)(q34;q11)[20] |
| 6 | 37/M | 86 | IFN + HU | 3,200 | 14.3 | 23.7 | 46,XY,t(9;22)(q34;q11)[20] |
| 7 | 68/F | 117 | HU | 4,600 | 9.5 | 10.7 | 46,XX,t(9;22)(q34;q11)[20] |
| 8 | 19/M | 0 | None | 138,800 | 12.4 | 54.2 | 46,XY,t(9;22)(q34;q11)[20] |
| 9 | 69/F | 65 | HU | 6,100 | 7.5 | 72.5 | 46,XX,t(8;9;22)(p23;q34;q11)[20] |
| 10 | 40/F | 0 | None | 37,800 | 8.6 | 30.9 | 46,XX,t(9;22)(q34;q11)[20] |
| 11 | 31/M | 0 | None | 67,500 | 14.6 | 32.0 | 46,XY,t(9;22)(q34;q11)[20] |
| 12 | 39/M | 0 | None | 104,800 | 13.3 | 17.1 | 46,XY,t(9;22)(q34;q11)[20] |
We used a standard technique for chromosome analysis. Aspirated BM was cultured overnight without stimulation and chromosome analysis was performed with the trypsin-treated G-banding method as described by ISCN (1995).
Abbreviations: Mos, months since diagnosis; IFN, interferon-α; HU, hydroxyurea; WBC, white blood cell count per microliter; Hb, hemoglobin (g/dL); Plt, platelets (104/μL).